Blinatumomab replacing chemotherapy improves survival in pediatric high-risk ALL

A randomized trial in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia compared replacing two cycles of chemotherapy with two cycles of blinatumomab after consolidation. The trial reported 4-year event-free survival of 83.0% with blinatumomab versus 70.3% with chemotherapy, along with lower rates of trial-treatment-related infection and life-threatening adverse events, though neurotoxic events were more frequent with blinatumomab.

Most relevant for: Pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia undergoing post-consolidation treatment.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.